Antivirals Global Market Report 2024

The antivirals market size has grown strongly in recent years. It will grow from $97.72 billion in 2023 to $105.73 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period of the anti-viral drug therapy market can be attributed to several key factors. These include the prevalence of viral diseases, growing public health concerns, patent expirations in the pharmaceutical industry, and government initiatives aimed at addressing viral infections.

The antivirals market size is expected to see strong growth in the next few years. It will grow to $143.83 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period for the anti-viral drug therapy market can be attributed to various factors. These include the emergence of new viral threats, ongoing global health initiatives, and the adoption of technological advances. Additionally, trends such as the expansion of telemedicine and digital health, as well as the development of personalized medicine, are expected to contribute to market growth.

The rising incidence of influenza is expected to drive the growth of the antiviral market. Influenza, commonly known as the flu, is a highly contagious viral respiratory infection caused by influenza viruses. Antiviral medications are used to treat influenza by inhibiting the replication and spread of these viruses within the body. For example, in the 2021-2022 flu season, there were 9 million flu cases, 4 million flu-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu-related deaths, as reported by the Centers for Disease Control and Prevention. This increasing incidence of influenza is a key factor contributing to the growth of the antiviral market.

The primary categories of anti-viral drug therapy include branded and generic medications. These drugs belong to different classes tailored for specific viral infections, including HIV, hepatitis, herpes, influenza, and more. Among these, reverse-transcriptase inhibitors (RTIs) are a noteworthy class used for treating HIV and, in some cases, hepatitis B infections.

The anti-viral drug therapy market research report is one of a series of new reports that provides anti-viral drug therapy market statistics, including anti-viral drug therapy industry global market size, regional shares, competitors with an anti-viral drug therapy market share, detailed anti-viral drug therapy market segments, market trends and opportunities, and any further data you may need to thrive in the anti-viral drug therapy industry. This anti-viral drug therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth of the anti-viral drug therapy market is expected to be driven by the increasing public-private funding for life science research on a global scale. Currently, there are no approved drugs or vaccines for the treatment of COVID-19, but there are multiple vaccines and drugs in various stages of development. Governments worldwide have allocated substantial grant funds to support research in the areas of vaccines, treatments, and diagnostics for COVID-19. For instance, in June 2021, several US government agencies and organizations, including the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA), invested over $3 billion in the research, development, and production of antiviral medications for COVID-19 as part of the Antiviral Program for Pandemics. Additionally, in October 2021, The Bill & Melinda Gates Foundation invested $120 million to support the development and manufacturing of antiviral drugs for COVID-19. This increased funding for life science research will accelerate research and development efforts, thereby promoting the growth of the market for COVID-19 antiviral drug therapy.

The market for antiviral drugs is being adversely affected by the emergence of alternative therapies such as naturopathy and homeopathy for the treatment of viral infections. The development of antiviral drugs for conditions like COVID-19 is associated with significant research and development (R&D) costs, high operational expenses, and substantial capital investments. Due to the substantial R&D expenses associated with drug development, there is a growing demand for alternative forms of treatment, including naturopathy and homeopathy. For instance, saikosaponins (A, B2, C, and D) are naturally occurring triterpene glycosides found in medicinal plants like Bupleurum spp., Heteromorpha spp., and Scrophularia scorodonia, and they have demonstrated antiviral activity against HCV-22E9. Saikosaponins work by inhibiting viral attachment and penetration stages. In contrast, marketed antiviral drugs are often priced significantly higher than their actual manufacturing costs. As a result, the availability and use of naturopathy and homeopathy medicines can pose a restraint on the growth of the antiviral drug market.

Companies operating in the antiviral drug therapy market are actively engaged in innovation driven by technological advancements to develop drugs targeting various viral infections. Biopharmaceutical companies are at the forefront of vaccine development for novel COVID-19 treatments. Technological progress in the pharmaceutical sector includes the creation of nucleic acid vaccines, which are based on DNA and RNA and enable the human body to generate vaccine antigens. For example, in October 2021, Merck & Co. Inc., a US-based pharmaceutical company, in collaboration with Ridgeback Biotherapeutics, a US-based biotechnology company, introduced Oral Antiviral Molnupiravir. This oral antiviral medication is intended for COVID-19 treatment and was granted emergency use authorization by the US Food and Drug Administration (FDA). Molnupiravir is an orally administered nucleoside analog designed to inhibit the replication of SARS-CoV-2, the virus responsible for COVID-19. This development reflects the industry's commitment to leveraging technological advances to address viral infections effectively.

Major companies operating in the antiviral market are committed to innovation, developing products such as PAXLOVID to provide reliable services to their customers. PAXLOVID is an antiviral pill used for the treatment of mild-to-moderate COVID-19. In November 2021, Pfizer Inc., a prominent US-based pharmaceutical company, introduced PAXLOVID after receiving approval from the US Food and Drug Administration (FDA). PAXLOVID is a crucial antiviral therapy that effectively treats COVID-19, reducing the risk of hospitalization and death. It is a combination therapy comprising two separate medications packaged together including nirmatrelvir and ritonavir. This innovation represents a significant step in combating COVID-19 and other viral infections.

In June 2022, Pfizer Inc., a leading US-based pharmaceutical company, completed its acquisition of ReViral Ltd. for $525 million. This strategic acquisition is part of Pfizer's effort to expand its anti-infective pipeline and strengthen its dedication to developing medications and vaccines for combating respiratory syncytial virus (RSV). ReViral Ltd., a UK-based company, specializes in the development of antiviral drugs. This acquisition enhances Pfizer's position in the fight against viral infections, particularly RSV, and represents a significant investment in the development of antiviral treatments.

Major companies operating in the antivirals market include AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

North America was the largest region in the anti-viral drug therapy market in 2023. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antivirals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The anti-viral drug therapy market consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.